NO962972L - Preparat for perkutan absorpsjon - Google Patents

Preparat for perkutan absorpsjon

Info

Publication number
NO962972L
NO962972L NO962972A NO962972A NO962972L NO 962972 L NO962972 L NO 962972L NO 962972 A NO962972 A NO 962972A NO 962972 A NO962972 A NO 962972A NO 962972 L NO962972 L NO 962972L
Authority
NO
Norway
Prior art keywords
derivative
preparation
percutaneous absorption
percutaneous
mixture
Prior art date
Application number
NO962972A
Other languages
English (en)
Norwegian (no)
Other versions
NO962972D0 (no
Inventor
Kaneto Uekama
Tetsumi Irie
Michio Hara
Yasuhide Horiuchi
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of NO962972D0 publication Critical patent/NO962972D0/no
Publication of NO962972L publication Critical patent/NO962972L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO962972A 1994-11-17 1996-07-16 Preparat for perkutan absorpsjon NO962972L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28379394 1994-11-17
PCT/JP1995/002350 WO1996015793A1 (en) 1994-11-17 1995-11-16 Percutaneously absorbable preparation

Publications (2)

Publication Number Publication Date
NO962972D0 NO962972D0 (no) 1996-07-16
NO962972L true NO962972L (no) 1996-09-16

Family

ID=17670220

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962972A NO962972L (no) 1994-11-17 1996-07-16 Preparat for perkutan absorpsjon

Country Status (15)

Country Link
US (1) US5854281A (de)
EP (1) EP0742011B1 (de)
JP (1) JP4024852B2 (de)
KR (1) KR100413202B1 (de)
CN (1) CN1102850C (de)
AT (1) ATE220911T1 (de)
AU (1) AU713461B2 (de)
CA (1) CA2181364A1 (de)
DE (1) DE69527507T2 (de)
ES (1) ES2180658T3 (de)
FI (1) FI962869A7 (de)
NO (1) NO962972L (de)
PT (1) PT742011E (de)
TW (1) TW413637B (de)
WO (1) WO1996015793A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0925788A4 (de) * 1997-03-13 1999-12-01 Toray Industries Arzneimittel zur behandlung von diabetischen vaskulären verletzungen
US6448251B1 (en) * 1997-11-28 2002-09-10 Peter T. Pugliese Zwitterionic-fatty acid compounds having anti-inflammatory properties
US6114337A (en) * 1998-11-27 2000-09-05 Pugliese; Peter T. Zwitteronic-fatty acid compounds having anti-inflammatory properties
HUP0103206A3 (en) * 1998-06-25 2002-11-28 Lavipharm Lab Inc Piscataway A device and method for the treatment of erectile dysfunction and for its making
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
DK1242012T3 (da) * 1999-11-24 2010-04-26 Agile Therapeutics Inc Forbedret transdermalt præventionsmiddelafgivelsessystem og fremgangsmåde
AU2002256471B2 (en) * 2001-05-03 2007-05-24 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
EP1390383B1 (de) 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense-permeationsverstärker
CN100477995C (zh) 2003-05-09 2009-04-15 东丽株式会社 增强剂
ATE437634T1 (de) * 2004-01-14 2009-08-15 Lavipharm Lab Inc Transdermale abgabevorrichtung für dihydropyridin-artige calcium-antagonisten mit 2 fettsäuren
KR20080000647A (ko) * 2005-04-28 2008-01-02 오노 야꾸힝 고교 가부시키가이샤 경피 흡수 제제
WO2007117706A2 (en) 2006-04-07 2007-10-18 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP2040731A4 (de) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd Feste orale dosierform mit einem verstärkungsmittel
CN102046192B (zh) 2008-05-07 2014-11-19 默里昂研究Ⅲ有限公司 GnRH相关化合物的组合物及制备方法
US20130274352A1 (en) * 2009-04-14 2013-10-17 The Regents Of The University Of California Oral Drug Devices and Drug Formulations
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2012094598A2 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
JP5878715B2 (ja) * 2011-09-22 2016-03-08 久光製薬株式会社 貼付剤
TWI569815B (zh) * 2012-03-22 2017-02-11 Teikoku Seiyaku Co Ltd Percutaneous absorption type preparation
CA2920284C (en) * 2013-08-09 2021-08-24 Teikoku Seiyaku Co., Ltd. Beraprost-containing patch
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
JP7176957B2 (ja) * 2016-12-28 2022-11-22 富士フイルム富山化学株式会社 外用組成物
US20230391809A1 (en) * 2022-06-07 2023-12-07 Biomimetix Jv, Llc Hydrophobic compositions including a hydrophilic active ingredient and methods relating thereto

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58124778A (ja) * 1982-01-20 1983-07-25 Toray Ind Inc 5,6,7−トリノル−4,8−インタ−m−フエニレンPGI↓2誘導体
ZA875317B (en) * 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
EP0267617B1 (de) * 1986-11-14 1992-06-24 Theratech, Inc. Erhöhung des Penetrationsvermögens mittels eines aus die Zellhülle verändernden Substanzen und kurzkettigen Alkoholen bestehenden binären Systems
JPH02503672A (ja) * 1987-06-01 1990-11-01 ワーナー‐ランバート・コンパニー 水性の系における浸透促進剤としての脂肪酸およびその短鎖エステル
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
JP2503672B2 (ja) 1989-07-28 1996-06-05 井関農機株式会社 草刈機の刈草収容装置
JPH0737389B2 (ja) * 1989-08-29 1995-04-26 久光製薬株式会社 プロスタグランジンe1含有の軟膏剤
JP2838297B2 (ja) * 1989-11-02 1998-12-16 日産化学工業株式会社 コルヒチン含有外用剤
JPH082801B2 (ja) * 1989-11-09 1996-01-17 株式会社資生堂 経皮吸収促進剤及び皮膚外用剤
JP3243564B2 (ja) * 1990-08-20 2002-01-07 リードケミカル株式会社 外用貼付剤
JP3059204B2 (ja) * 1990-10-25 2000-07-04 帝國製薬株式会社 安定なプロスタグランジンi▲下1▼類含有皮膚適用組成物
JPH04243827A (ja) * 1991-01-25 1992-08-31 Sumitomo Pharmaceut Co Ltd プロスタグランジン誘導体含有溶解型軟膏剤
DE4124693A1 (de) * 1991-07-22 1993-01-28 Schering Ag Carbacyclinderivate als mittel zur behandlung von vitiligo
DE4124695C2 (de) * 1991-07-22 1994-12-22 Blitstein Willinger Eveline Dr Verwendung von Carbacyclinderivaten zur Behandlung von Psoriasis vulgaris
DE4210165A1 (de) * 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme
CA2107669C (en) * 1992-02-07 2004-06-01 Makoto Okumura Preparation for treating wounds and hemorrhoides
JP3102141B2 (ja) * 1992-05-29 2000-10-23 東レ株式会社 養毛育毛剤
JP3115482B2 (ja) * 1994-01-28 2000-12-04 帝人株式会社 プロスタサイクリン類含有皮膚適用組成物

Also Published As

Publication number Publication date
ATE220911T1 (de) 2002-08-15
EP0742011B1 (de) 2002-07-24
EP0742011A1 (de) 1996-11-13
DE69527507T2 (de) 2002-11-07
PT742011E (pt) 2002-10-31
AU713461B2 (en) 1999-12-02
TW413637B (en) 2000-12-01
NO962972D0 (no) 1996-07-16
CN1102850C (zh) 2003-03-12
US5854281A (en) 1998-12-29
DE69527507D1 (de) 2002-08-29
AU3881195A (en) 1996-06-17
FI962869A0 (fi) 1996-07-16
EP0742011A4 (de) 1997-08-20
FI962869L (fi) 1996-09-16
WO1996015793A1 (en) 1996-05-30
CA2181364A1 (en) 1996-05-30
FI962869A7 (fi) 1996-09-16
KR100413202B1 (ko) 2004-04-13
ES2180658T3 (es) 2003-02-16
JP4024852B2 (ja) 2007-12-19
CN1140412A (zh) 1997-01-15

Similar Documents

Publication Publication Date Title
NO2011006I1 (no) Pitavastin, valgfritt i form av av farmasøytisk akseptabelt salt eller ester
NO923809L (no) Farmasoeytisk preparat
CA2124690A1 (en) Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
NO971951L (no) Farmasöytiske preparater
GB9601120D0 (en) Organic compounds
PE20001032A1 (es) Composiciones y metodos para tratar enfermedades pulmonares
ES2102919T3 (es) Composicion acida a base de vesiculas lipidicas y su utilizacion en aplicacion topica
BG48811A3 (bg) Метод за получаване на 2-бром-алфа-ергокриптини
PT1039895E (pt) Utilizacao de acidos 3-benzoilfenilaceticos respectivos esteres ou amidas para o tratamento do glaucoma glc1a
CA2005811A1 (en) Cosmetic composition
CA2044428A1 (en) Coating composition
ES2159919T3 (es) Procedimiento para la preparacion de compuestos de tipo ceramidas.
CA2315871A1 (en) Methods, compositions, and kits for enhancing female sexual desire and responsiveness
DE69434556D1 (de) Zusammensetzung zur Wasserdichtung und Konservierung
CA2086803A1 (en) Cysteamine Permanent Wave Composition and Method
ATE117207T1 (de) Stabile azelastinhydrochlorid-zubereitung.
AU1438699A (en) Fatty acid uninterrupted by a methylene as anti-inflammatory agents in superficial tissues of mammals
DK0646593T3 (da) Corticoid-17,21-dicarboxylsyreestere, fremgangsmåder til deres fremstilling og lægemidler indeholdende dem
CA2360300A1 (en) A transdermal composition of an antivomiting agent and a preparation containing the same
CA2141788A1 (en) Controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine and methods of use
US5519054A (en) Pharmaceutical compositions containing N-acetyl-cysteine derivatives useful for the treatment of cataract
BR0011174A (pt) Composições, compostos, compostos isolados e métodos para controlar pestes
EP0757987A4 (de) Pyrazolcarbonsäurederivat und ein mittel zur bekämpfung von pflanzenkrankheiten
CA2324556A1 (en) An environment friendly acaricide formulation
CA2282840A1 (en) S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide as a 5-ht2 receptor antagonist

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application